Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.67 and traded as high as $0.70. Brainstorm Cell Therapeutics shares last traded at $0.6939, with a volume of 6,316 shares changing hands.
Brainstorm Cell Therapeutics Trading Down 0.6%
The firm’s 50-day moving average price is $0.80 and its 200 day moving average price is $0.68. The company has a market capitalization of $7.61 million, a price-to-earnings ratio of -0.21 and a beta of 0.22.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Recommended Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
